• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President, CEO Shelton Jerrell exercised 389,720 shares at a strike of $5.00 and sold $2,289,781 worth of shares (339,720 units at $6.74), increasing direct ownership by 6% to 912,419 units (SEC Form 4)

    6/20/25 8:15:11 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SHELTON JERRELL

    (Last) (First) (Middle)
    C/O CRYOPORT INC.
    112 WESTWOOD PLACE, SUITE 350

    (Street)
    BRENTWOOD TN 37027

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cryoport, Inc. [ CYRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/17/2025 M 50,000(1) A $5 912,419 D
    Common Stock 06/17/2025 M 151,304(2) A $5 1,063,723 D
    Common Stock 06/17/2025 S 151,304(2) D $6.8056(3) 912,419 D
    Common Stock 06/18/2025 M 119,281(2) A $5 1,031,700 D
    Common Stock 06/18/2025 S 119,281(2) D $6.812(4) 912,419 D
    Common Stock 06/20/2025 M 69,135(2) A $5 981,554 D
    Common Stock 06/20/2025 S 69,135(2) D $6.4732(5) 912,419 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $5 06/17/2025 M 50,000(1) (6) 08/20/2025 Common Stock 50,000 $0.00 506,064 D
    Stock Option (right to buy) $5 06/17/2025 M 151,304(2) (6) 08/20/2025 Common Stock 151,304 $0.00 354,760 D
    Stock Option (right to buy) $5 06/18/2025 M 119,281(2) (6) 08/20/2025 Common Stock 119,281 $0.00 235,479 D
    Stock Option (right to buy) $5 06/20/2025 M 69,135(2) (6) 08/20/2025 Common Stock 69,135 $0.00 166,344 D
    Explanation of Responses:
    1. This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
    2. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on June 3, 2025.
    3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.96, inclusive.
    4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $6.97, inclusive.
    5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.33 to $6.83, inclusive.
    6. 1/48 of the options vested on the 19th of each month for forty-eight months beginning on 8/19/2015.
    Remarks:
    With respect to prices reported as weighted average prices in Table I, the reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the applicable footnotes to this Form 4.
    /s/ Jerrell Shelton 06/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CYRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    5/3/2024$22.00 → $19.00Buy → Neutral
    B. Riley Securities
    4/4/2024$17.00 → $21.00Buy
    Jefferies
    3/13/2024$19.00 → $18.00Buy
    Needham
    More analyst ratings

    $CYRX
    SEC Filings

    See more
    • CryoPort Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cryoport, Inc. (0001124524) (Filer)

      6/13/25 3:55:20 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cryoport, Inc. (0001124524) (Filer)

      6/10/25 9:00:27 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by CryoPort Inc.

      SD - Cryoport, Inc. (0001124524) (Filer)

      5/30/25 4:31:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Shelton Jerrell exercised 389,720 shares at a strike of $5.00 and sold $2,289,781 worth of shares (339,720 units at $6.74), increasing direct ownership by 6% to 912,419 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/20/25 8:15:11 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mandalam Ramkumar sold $75,348 worth of shares (10,712 units at $7.03), decreasing direct ownership by 14% to 66,377 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/13/25 7:00:49 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Digital and Tech Officer Zecchini Edward J exercised 75,000 shares at a strike of $3.07 and sold $352,518 worth of shares (51,500 units at $6.84), increasing direct ownership by 35% to 90,411 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/10/25 7:28:18 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cryoport upgraded by UBS with a new price target

      UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00

      3/24/25 8:25:01 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Cryoport with a new price target

      Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:39 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Cryoport with a new price target

      Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:29 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care